This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

Phase 1 Terminated 8 enrolled Boehringer Ingelheim

Non-randomizedSequentialOpen-labelTreatment

Summary

The main objective of this study is to determine the biodistribution and intra-tumor accumulation of \[89Zr\]Zr-BI 754111 at baseline and its change upon treatment

Timeline

Start: 2019-01-22
Primary completion: 2020-02-19
Completion: 2020-12-08

Publications

Miedema IHC, Huisman MC, Zwezerijnen GJC, Grempler R, Pitarch AP, Thiele A, Hesse R, Elgadi M, Peltzer A, Vugts DJ, van Dongen GAMS, de Gruijl TD, Menke-van der Houven van Oordt CW, Bahce I. 89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC. Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):2068-2080. doi: 10.1007/s00259-023-06164-w. Epub 2023 Mar 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BI 754111	Unknown	40 mg	—
Subject	BI 754111	Unknown	600 mg	—
Subject	[89Zr]Zr-BI 754111	Unknown	4 mg	—
Subject	[89Zr]Zr-BI 754111	Unknown	37 mbq	—
Background	Ezabenlimab	Monoclonal antibody	240 mg	—

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

Summary

Timeline

Publications

Drugs

Indications